How The SOL-1 Readout Is Reframing The Story For Ocular Therapeutix (OCUL) [Yahoo! Finance]
Ocular Therapeutix, Inc. (OCUL)
Last ocular therapeutix, inc. earnings: 3/12 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ocutx.com
Company Research
Source: Yahoo! Finance
Ocular Therapeutix's latest update keeps the model fair value anchored at US$26.0 per share, signaling that core assumptions around Axpaxli and the broader pipeline are largely intact despite recent volatility. Analysts linking this steady fair value to the detailed SOL-1 Phase 3 readout point to a mix of optimism on approval odds and dosing profile, alongside tougher questions about how the therapy might stack up against Eylea in real world use. As you read on, you will see how to track this evolving story and what to watch as the narrative shifts with new data. Stay updated as the Fair Value for Ocular Therapeutix shifts by adding it to your watchlist or portfolio . Alternatively, explore our Community to discover new perspectives on Ocular Therapeutix. What Wall Street Has Been Saying ?? Bullish Takeaways BofA, Clear Street, Jefferies, and Citizens all reaffirm positive ratings after the SOL-1 data, signaling continued institutional confidence around Axpaxli and the broade
Show less
Read more
Impact Snapshot
Event Time:
OCUL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OCUL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OCUL alerts
High impacting Ocular Therapeutix, Inc. news events
Weekly update
A roundup of the hottest topics
OCUL
News
- Ocular Therapeutix Inc. (OCUL) Appears Highly Attractive Following SOL-1 Clinical Trial Data [Yahoo! Finance]Yahoo! Finance
- Ocular Therapeutix™ Announces First Patient Enrolled in SOL-X Long-Term Extension Trial for AXPAXLI™ in Wet AMDGlobeNewswire
- Ocular Therapeutix™ to Report First Quarter 2026 Financial Results on May 5, 2026GlobeNewswire
- Ocular Therapeutix Says FDA Talks Progressing as It Eyes AXPAXLI NDA for Wet AMD on SOL-1 Data [Yahoo! Finance]Yahoo! Finance
- Ocular Therapeutix™ to Participate in May Scientific and Investor ConferencesGlobeNewswire
OCUL
Earnings
- 11/4/25 - Beat
OCUL
Sec Filings
- 4/13/26 - Form 4
- 3/27/26 - Form SCHEDULE
- 2/27/26 - Form 8-K
- OCUL's page on the SEC website